Key Highlights
- Loss of USD 0.28 per share narrowed from USD 1.84 and beat the consensus estimate of a USD 0.85 loss.
- Net loss fell to USD 7.6 million from USD 21.8 million, helped by a non-cash USD 12.7 million Warrant gain.
- Operating expenses were USD 20.4 million, with Research and Development at USD 12.7 million and G&A at USD 7.7 million.
- Cash, cash equivalents and restricted cash totaled USD 108.0 million, and the company said funding reaches through 2028.
Precision BioSciences, Inc. (NASDAQ:DTIL) reported a third quarter 2026 net loss of USD 7.6 million, or USD 0.28 per share, against a net loss of USD 21.8 million, or USD 1.84 per share, a year earlier. The loss per share was narrower than a consensus estimate of a loss of USD 0.85. The clinical stage gene editing company recognized no Revenue in the quarter, compared with USD 13 thousand a year earlier.
The improvement came from other income rather than operations. A non-cash gain of USD 12.7 million on the change in Fair Value of the warrant liability, against a USD 1.2 million loss a year earlier, more than offset an operating loss of USD 20.4 million. Nine month revenue was USD 10.8 million against USD 0.06 million, reflecting amounts recognized under the TG Therapeutics license agreement and a legacy agriculture gene editing agreement.
Spending Shifted Toward the Hepatitis B Program
Research and development expenses fell to USD 12.7 million from USD 13.4 million. Direct external costs for PBGENE-HBV rose to USD 3.0 million from USD 1.6 million as the ELIMINATE-B trial enrolled additional patients and expanded the 0.4 mg/kg and 0.65 mg/kg cohorts, while PBGENE-DMD external costs eased to USD 3.5 million from USD 3.7 million. Spending on contract manufacturers and outsourced research fell to USD 0.15 million from USD 0.8 million. General and administrative expenses rose to USD 7.7 million from USD 7.3 million on employee and consulting costs.
For the nine months, net loss was USD 58.7 million, or USD 2.26 per share, against USD 65.9 million, or USD 6.14 per share, and net cash used in Operating Activities fell to USD 40.5 million from USD 54.6 million.
Clinical Milestones and Funding Position
The first patient in the Phase 1/2 FUNCTION-DMD study was dosed in August 2026, with initial safety data targeted for year end 2026 and efficacy data at distinct timepoints in the first and second halves of 2027. The PBGENE-HBV abstract was selected for a late-breaking oral presentation at the AASLD Liver Meeting 2026. The company earned a USD 7.5 million payment under its license agreement with TG Therapeutics, which is evaluating azer-cel in progressive multiple sclerosis.
The company said existing cash, continued expense discipline and its at-the-market Facility support funding of operating needs through 2028, while noting that additional Capital may be needed and that financing is not assured. The 2024 Term Loan carried USD 22.5 million of principal at a 5.50% stated rate.
Cash, Burn and Dated Events Against Prior Figures
Cash, cash equivalents and restricted cash of USD 108.0 million compares with USD 137.2 million at the start of the year, a decline of USD 29.1 million against a USD 37.3 million decline in the first nine months of 2025. Unrestricted cash stood at USD 81.7 million against USD 110.8 million at December 31, 2025. The accumulated Deficit reached USD 586.9 million. The PBGENE-HBV abstract becomes public on November 5, 2026, with the oral presentation on November 8, 2026, and initial FUNCTION-DMD safety data are targeted for year end 2026.




_11_13_2026_20_27_09_053340.jpg)

Please wait processing your request...